|Day Low/High||140.76 / 144.20|
|52 Wk Low/High||114.53 / 202.20|
Since the election, big questions remain about investing in hospital and healthcare stocks, and the group will remain volatile according to Mizuho.
Doug Kass shares his thoughts on closed-end municipal bond funds.
Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.
Cramer shares his views on price war victims. Nike, Allergan and Netflix are among the stocks discussed.
Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.
Stocks in the health care sector seem to have no underpinnings whatsoever.
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.
Today there was a virtual vacuum of good news in the stock market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.
Valeant shares drop as regulators investigate possible accounting fraud.
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
Jim Cramer says health care stocks could see a temporary relief rally, but may be susceptible to further downside.
I continue to believe downside risks far outweigh the risks of a near-term rally.
In a "take no pain, take no prisoners" market, health care stocks languish.
We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.
Drug wholesalers are battling it out, while Avon is looking better, says Jim Cramer.
Cramer previews important earnings reports scheduled for the coming week.
McKesson Corp. (MCK) hit a 52-week low Friday, falling 23% Friday, hitting $114 per share before bouncing back to $124.57 before market's close.
Shares of the drug distributor were falling sharply Friday.
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.